Histone acetyltransferase 1 (HAT1) is an enzyme which acetylates lysine on histone proteins and is intricately involved with regulating gene transcription.
Researchers in the Sunwoo Lab have developed a method to differentiate intra-epithelial innate lymphoid cells type 1 (ieILC1s) from conventional peripheral natural kills cells for immunotherapeutic purposes.
Stanford researchers at the Dionne Lab have developed a new hand-held technology that uses optical characterization to rapidly and quantitatively measure extracted viral-RNA target binding or antibody binding to nanofabricated platforms.
Stanford researchers have developed a portable hybrid frame-event based near eye gaze tracking system that has a superior speed while using a lower data bandwidth. They demonstrated real time results for gaze-tracking.
Stanford researchers have created an integrated cooling textile (called i-Cool) with an unique functional design for personal perspiration management (PPM).
The Ji lab has developed a sequencing assay to provide genetic diversity information of microsatellite and chromosomal instability (MSI) in colorectal cancer. MSI arises from a loss of DNA mismatch repair in colorectal cancers, making them genetically diverse.
Radiation therapy is a common option in diseases like breast cancer, but can also cause significant damage to the skin. Permanent scarring and fibrosis can result, with both aesthetic and functional consequences for cancer patients.
Neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) have been characterized by the expansion of the GGGGCC hexanucleotide repeat within the non-coding region of the human chromosome 9 open reading frame 72 (C9ORF72) gene.
Researchers at Stanford have developed, for the first time, a high-throughput method to systematically detect and identify silencer elements in the human genome.
These dual-function nanoparticles improve selectivity of myeloid treatment via identification and reduction of tumor progression in a two-step process: initial accumulation in tumor microenvironments, followed by targeted delivery of a therapeutic payload.